Live‐attenuated influenza viruses as delivery vectors for Chlamydia vaccines
- 23 April 2007
- journal article
- research article
- Published by Wiley in Immunology
- Vol. 122 (1) , 28-37
- https://doi.org/10.1111/j.1365-2567.2007.02608.x
Abstract
Effective delivery systems are needed to design efficacious vaccines against the obligate intracellular bacterial pathogen, Chlamydia trachomatis. Potentially effective delivery vehicles should promote the induction of adequate levels of mucosal T-cell and antibody responses that mediate long-term protective immunity. Antigen targeting to the nasal-associated lymphoid tissue (NALT) is effective for inducing high levels of specific immune effectors in the genital mucosa, and therefore suitable for vaccine delivery against genital chlamydial infection. We tested the hypothesis that live attenuated influenza A viruses are effective viral vectors for intranasal delivery of subunit vaccines against genital chlamydial infection. Recombinant influenza A/PR8/34 (H1N1) viruses were generated by insertion of immunodominant T-cell epitopes from chlamydial major outer membrane protein into the stalk region of the neuraminidase gene. Intranasal immunization of mice with viral recombinants resulted in a strong T helper 1 (Th1) response against intact chlamydial elementary bodies. Also, immunized mice enjoyed a significant state of protective immunity (P > 0.002) by shedding less chlamydiae and rapidly clearing the infection. Furthermore, a high frequency of Chlamydia-specific Th1 was measured in the genital mucosal and systemic draining lymphoid tissues within 24 hr after challenge of vaccinated mice. Moreover, multiple epitope delivery provided a vaccine advantage over single recombinants. Besides, long-term protective immunity correlated with the preservation of a robustly high frequency of specific Th1 cells and elevated immunoglobulin G2a in genital secretions. Because live attenuated influenza virus vaccines are safe and acceptable for human use, they may provide a new and reliable approach to deliver efficacious vaccines against sexually transmitted diseases.Keywords
This publication has 55 references indexed in Scilit:
- Reinfections, Persistent Infections, and New Infections After General Population Screening for Chlamydia trachomatis Infection in The NetherlandsSexually Transmitted Diseases, 2005
- Immunoepidemiologic Profile ofChlamydia trachomatisInfection: Importance of Heat‐Shock Protein 60 and Interferon‐γThe Journal of Infectious Diseases, 2005
- Interaction between Components of the Type III Secretion System ofChlamydiaceaeJournal of Bacteriology, 2005
- Human Antibody Responses to a Chlamydia-Secreted Protease FactorInfection and Immunity, 2004
- Exploitation of Nucleic Acid Packaging Signals To Generate a Novel Influenza Virus-Based Vector Stably Expressing Two Foreign GenesJournal of Virology, 2003
- Activation of Tumor Antigen-Specific Cytotoxic T Lymphocytes (CTLs) by Human Dendritic Cells Infected with an Attenuated Influenza A Virus Expressing a CTL Epitope Derived from the HER-2/neu Proto-OncogeneJournal of Virology, 2003
- Immunization with theChlamydia trachomatisMouse Pneumonitis Major Outer Membrane Protein Can Elicit a Protective Immune Response against a Genital ChallengeInfection and Immunity, 2001
- Chlamydial Genomics and Vaccine Antigen DiscoveryThe Journal of Infectious Diseases, 2000
- Use of a Mouse Lung Challenge Model to Identify Antigens Protective againstChlamydia pneumoniaeLung InfectionThe Journal of Infectious Diseases, 2000
- Priming withChlamydia trachomatisMajor Outer Membrane Protein (MOMP) DNA followed by MOMP ISCOM Boosting Enhances Protection and Is Associated with Increased Immunoglobulin A and Th1 Cellular Immune ResponsesInfection and Immunity, 2000